drugset / Trial / NCT00002412

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

NCT00002412

Phase 2 Completed Triangle Pharmaceuticals
Double-blindTreatment

Summary

The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Emivirine Small molecule
Background Didanosine Small molecule
Background Hydroxyurea Other / unclassified
Background Stavudine Other / unclassified